Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARK: SRP-9001 gene therapy in ambulatory boys with Duchenne muscular dystrophy
jRCT2053210141Phase 3Completed
- Sponsor
- Sarepta Therapeutics
- Start
- Jul 2022
- Modality
- Gene Therapies
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Immediate SRP-9001 with Initial placebo with delayed SRP-9001 (2 arms). Primary endpoint: Change From Baseline in NSAA Total Score at Week 52 (Part 1). Started Jul 2022; status: completed.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2053210141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053210141.